Tags

Type your tag names separated by a space and hit enter

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
Respir Res. 2018 Oct 05; 19(1):196.RR

Abstract

BACKGROUND

Use of inhaled corticosteroids (ICS) increases the risk of pneumonia in chronic obstructive pulmonary disease (COPD), but the magnitude of risk with different ICS remains unclear.

METHODS

A post hoc analysis of the 4-year UPLIFT® trial to assess whether pneumonia risk differed by type of ICS (fluticasone propionate [FP], other ICS, or no ICS) in permanent users (defined by use until end of study) or in users at baseline (sensitivity analysis).

RESULTS

For the permanent-users analysis, 825 patients receiving FP throughout the trial, 825 patients receiving other ICS and 825 patients not receiving ICS were matched on relevant baseline features 1:1:1. A significantly greater risk of pneumonia was observed for FP versus no ICS: the hazard ratio (HR) for risk of pneumonia was 1.33 (95% confidence interval [CI] 1.00, 1.75; p = 0.046) and the rate ratio (RR) was 1.58 (95% CI 1.05, 2.37; p = 0.028). A greater risk was also found for FP versus other ICS: HR 1.28 (95% CI 0.97, 1.68; p = 0.078) and RR 1.48 (95% CI 1.00, 2.19; p = 0.049). A higher proportion of patients on FP were hospitalized with pneumonia (7.9%) versus other ICS (6.7%) or no ICS (5.9%). Whilst other ICS use was associated with the highest number of fatal pneumonia events, the total number of fatal pneumonia incidents was low. A similar pattern was observed in the sensitivity analyses, which included 4002 patients on different treatments at baseline (FP, other ICS, and no ICS) and considered potential switches during the study.

CONCLUSION

The results support existing evidence of an increased pneumonia risk with FP use compared with other ICS and no ICS use in patients with COPD. Healthcare professionals should evaluate the risk-benefit ratio of using ICS when making treatment decisions with their patients.

TRIAL REGISTRATION

Post hoc analysis of UPLIFT®. ClinicalTrials.gov number: NCT00144339 . Retrospectively registered September 2, 2005.

Authors+Show Affiliations

Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA, 90095-1690, USA. dtashkin@mednet.ucla.edu.Pneumology Department, Hospital Universitari Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.Brigham and Women's Hospital, Boston, MA, USA.TA Respiratory/Biosimilars, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.Biostatistics and Data Sciences Europe, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.Royal Devon and Exeter Hospital, Exeter, UK.Pulmonary/Critical Care, University of Texas, and South Texas Veterans Health Care System, San Antonio, TX, USA.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

30290801

Citation

Tashkin, Donald P., et al. "Concomitant Inhaled Corticosteroid Use and the Risk of Pneumonia in COPD: a Matched-subgroup Post Hoc Analysis of the UPLIFT® Trial." Respiratory Research, vol. 19, no. 1, 2018, p. 196.
Tashkin DP, Miravitlles M, Celli BR, et al. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respir Res. 2018;19(1):196.
Tashkin, D. P., Miravitlles, M., Celli, B. R., Metzdorf, N., Mueller, A., Halpin, D. M. G., & Anzueto, A. (2018). Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respiratory Research, 19(1), 196. https://doi.org/10.1186/s12931-018-0874-0
Tashkin DP, et al. Concomitant Inhaled Corticosteroid Use and the Risk of Pneumonia in COPD: a Matched-subgroup Post Hoc Analysis of the UPLIFT® Trial. Respir Res. 2018 Oct 5;19(1):196. PubMed PMID: 30290801.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. AU - Tashkin,Donald P, AU - Miravitlles,Marc, AU - Celli,Bartolomé R, AU - Metzdorf,Norbert, AU - Mueller,Achim, AU - Halpin,David M G, AU - Anzueto,Antonio, Y1 - 2018/10/05/ PY - 2018/07/03/received PY - 2018/08/27/accepted PY - 2018/10/7/entrez PY - 2018/10/7/pubmed PY - 2019/1/10/medline KW - COPD KW - Fluticasone propionate KW - Inhaled corticosteroids KW - Pneumonia KW - UPLIFT® SP - 196 EP - 196 JF - Respiratory research JO - Respir Res VL - 19 IS - 1 N2 - BACKGROUND: Use of inhaled corticosteroids (ICS) increases the risk of pneumonia in chronic obstructive pulmonary disease (COPD), but the magnitude of risk with different ICS remains unclear. METHODS: A post hoc analysis of the 4-year UPLIFT® trial to assess whether pneumonia risk differed by type of ICS (fluticasone propionate [FP], other ICS, or no ICS) in permanent users (defined by use until end of study) or in users at baseline (sensitivity analysis). RESULTS: For the permanent-users analysis, 825 patients receiving FP throughout the trial, 825 patients receiving other ICS and 825 patients not receiving ICS were matched on relevant baseline features 1:1:1. A significantly greater risk of pneumonia was observed for FP versus no ICS: the hazard ratio (HR) for risk of pneumonia was 1.33 (95% confidence interval [CI] 1.00, 1.75; p = 0.046) and the rate ratio (RR) was 1.58 (95% CI 1.05, 2.37; p = 0.028). A greater risk was also found for FP versus other ICS: HR 1.28 (95% CI 0.97, 1.68; p = 0.078) and RR 1.48 (95% CI 1.00, 2.19; p = 0.049). A higher proportion of patients on FP were hospitalized with pneumonia (7.9%) versus other ICS (6.7%) or no ICS (5.9%). Whilst other ICS use was associated with the highest number of fatal pneumonia events, the total number of fatal pneumonia incidents was low. A similar pattern was observed in the sensitivity analyses, which included 4002 patients on different treatments at baseline (FP, other ICS, and no ICS) and considered potential switches during the study. CONCLUSION: The results support existing evidence of an increased pneumonia risk with FP use compared with other ICS and no ICS use in patients with COPD. Healthcare professionals should evaluate the risk-benefit ratio of using ICS when making treatment decisions with their patients. TRIAL REGISTRATION: Post hoc analysis of UPLIFT®. ClinicalTrials.gov number: NCT00144339 . Retrospectively registered September 2, 2005. SN - 1465-993X UR - https://www.unboundmedicine.com/medline/citation/30290801/Concomitant_inhaled_corticosteroid_use_and_the_risk_of_pneumonia_in_COPD:_a_matched_subgroup_post_hoc_analysis_of_the_UPLIFT®_trial_ L2 - https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-018-0874-0 DB - PRIME DP - Unbound Medicine ER -